Literature DB >> 17618422

On the concept of remission in schizophrenia.

Stefan Leucht1, Romain Beitinger, Werner Kissling.   

Abstract

RATIONALE: Criteria for remission in schizophrenia have recently been presented. It is unclear how many acutely ill patients meet these criteria and how they compare with previously suggested definitions. OBJECTIVES AND METHODS: We re-analysed seven anti-psychotic drug trials (n = 1,708) of patients with schizophrenia to find out how many met the new remission criteria and their single components, how many met two previously used remission criteria, and how many met simpler measures of response (at least 50% Brief Psychiatric Rating Scale [BPRS] reduction, a Clinical Global Impressions [CGI] improvement score of at least 'much better' or a CGI severity score of 'mild or better').
RESULTS: Thirty-seven percent/41% (last observation carried forward [LOCF]/completer analysis [CO]) of the initially acutely ill patients with positive symptoms met the severity criteria of remission at 4 weeks, and 27%/52% (worst case/CO) met the severity and time criteria at 1 year. Only 13%/21% (LOCF) met the severity criteria at 4 weeks/1 year when an item threshold 'at best very mild symptoms' was applied, and almost no patients were absolutely symptom-free. The psychotic symptoms component was more difficult to achieve than the negative component. The criteria were more stringent than 'at least 50% BPRS reduction' and than 'CGI improvement score of at least much better.' However, the definition 'CGI severity score mild or better' was of a stringency similar to the new remission criteria, which probably explains why fewer patients met previously defined criteria that included this scale.
CONCLUSION: The new remission criteria proved to be an achievable goal for clinical trials. A consensus on the application of their time component is still needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17618422     DOI: 10.1007/s00213-007-0857-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia.

Authors:  Gopalan Sethuraman; Cindy C Taylor; Mark Enerson; Eduardo Dunayevich
Journal:  Schizophr Res       Date:  2005-07-28       Impact factor: 4.939

2.  Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group.

Authors:  H J Möller; P Boyer; O Fleurot; W Rein
Journal:  Psychopharmacology (Berl)       Date:  1997-08       Impact factor: 4.530

3.  Direct transition to long-acting risperidone--analysis of long-term efficacy.

Authors:  W Kissling; S Heres; K Lloyd; E Sacchetti; P Bouhours; R Medori; P M Llorca
Journal:  J Psychopharmacol       Date:  2005-09       Impact factor: 4.153

4.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

5.  A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia.

Authors:  J Peuskens; C G Link
Journal:  Acta Psychiatr Scand       Date:  1997-10       Impact factor: 6.392

6.  Remission criteria for schizophrenia: evaluation in a large naturalistic cohort.

Authors:  Marc De Hert; Ruud van Winkel; Martien Wampers; John Kane; Jim van Os; Joseph Peuskens
Journal:  Schizophr Res       Date:  2007-03-02       Impact factor: 4.939

7.  Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study.

Authors:  J M Haro; E T Edgell; D Novick; J Alonso; L Kennedy; P B Jones; M Ratcliffe; A Breier
Journal:  Acta Psychiatr Scand       Date:  2005-03       Impact factor: 6.392

8.  Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

Authors:  P Carrière; D Bonhomme; T Lempérière
Journal:  Eur Psychiatry       Date:  2000-08       Impact factor: 5.361

Review 9.  Establishment of remission criteria for anxiety disorders.

Authors:  Alicia C Doyle; Mark H Pollack
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384

10.  Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.

Authors:  A Delcker; M L Schoon; B Oczkowski; H J Gaertner
Journal:  Pharmacopsychiatry       Date:  1990-05       Impact factor: 5.788

View more
  14 in total

Review 1.  Unanswered questions in schizophrenia clinical trials.

Authors:  John M Kane; Stefan Leucht
Journal:  Schizophr Bull       Date:  2008-01-16       Impact factor: 9.306

Review 2.  Methodological issues in current antipsychotic drug trials.

Authors:  Stefan Leucht; Stephan Heres; Johannes Hamann; John M Kane
Journal:  Schizophr Bull       Date:  2008-01-29       Impact factor: 9.306

Review 3.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

4.  [Response and remission in schizophrenic subjects].

Authors:  J Zimmermann; A Wolter; N R Krischke; U W Preuss; T Wobrock; P Falkai
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

5.  Managing schizophrenia in primary care: the utility of remission criteria as outcome indicators.

Authors:  Christopher Fear; David Yeomans; Bryan Moore; Mark Taylor; Keith Ford; Alan Currie; Joanne Hynes; Gary Sullivan; Richard Whale; Tom Burns
Journal:  Ment Health Fam Med       Date:  2009-06

Review 6.  Quantifying clinical relevance in the treatment of schizophrenia.

Authors:  Christoph U Correll; Taishiro Kishimoto; Jimmi Nielsen; John M Kane
Journal:  Clin Ther       Date:  2011-12       Impact factor: 3.393

7.  The SWITCH study: rationale and design of the trial.

Authors:  Stephan Heres; Diana Meliu Cirjaliu; Liana Dehelean; Valentin Petre Matei; Delia Marina Podea; Dorina Sima; Lynne Stecher; Stefan Leucht
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-07-31       Impact factor: 5.270

8.  Symptomatic remission in a multiracial urban population of older adults with schizophrenia.

Authors:  Azziza Bankole; Carl I Cohen; Ipsit Vahia; Shilpa Diwan; Nikhil Palekar; Pia Reyes; Mamta Sapra; Paul M Ramirez
Journal:  Am J Geriatr Psychiatry       Date:  2008-12       Impact factor: 4.105

Review 9.  The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.

Authors:  Stefan Leucht; Inge Winter-van Rossum; Stephan Heres; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; F Markus Leweke; Shôn Lewis; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Shitij Kapur; René S Kahn; Iris E Sommer
Journal:  Schizophr Bull       Date:  2015-03-18       Impact factor: 9.306

Review 10.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.